医药行业周报：预期修正，关注长期价值

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of March 9, 2026 [1]. Core Insights - The report highlights a strong trend in China's innovative pharmaceuticals going global, with 39 license-out transactions recorded by mid-February 2026, totaling approximately $29.53 billion in upfront payments and over $49 billion in total deal value [2]. - Despite the positive outlook for innovative drug exports, the innovative drug index has declined by 4.84% as of March 4, 2026, underperforming the CSI 300 index by 4.25 percentage points, indicating a divergence between market sentiment and fundamentals [2]. - The report emphasizes the importance of clinical data validation and milestone payments in the upcoming phase for innovative drugs, particularly following the surge in outbound licensing activities [2]. Summary by Sections 1. Market Trends - The report notes that the pharmaceutical retail market in China saw a retail scale of 588 billion yuan in December 2025, marking a 4.3% year-on-year growth, although the overall annual growth rate was slightly negative at -0.57% [7]. - The report indicates that the average transaction price in retail pharmacies decreased by 6% in 2025, influenced by a decline in the purchase frequency of consumer goods like health products [7]. 2. Supply Chain Dynamics - The report discusses the impact of macroeconomic changes on the supply side, noting that 90% of monitored chemical products experienced price increases as of March 6, 2026, with the chemical products price index rising by 14.1% since the beginning of the year [3]. - It highlights that the pricing strategy in the raw material drug sector is crucial for long-term development, especially in light of rising upstream costs [3]. 3. Regulatory Environment - The report mentions the management of dual-use items, which has led to significant price discrepancies between domestic and international markets, potentially benefiting domestic medical product manufacturers [4]. - It also notes that the regulatory environment is becoming stricter, particularly for key materials, which could enhance the competitive advantage of domestic products [4]. 4. Innovative Drug Development - The report highlights the emergence of oral GLP-1 drugs, with significant sales growth for Eli Lilly's products, and notes that Chinese companies are actively pursuing GLP-1 research and development [5]. - It emphasizes the ongoing collaborations in the small nucleic acid field, with several significant partnerships and acquisitions taking place in early 2026 [6]. 5. Stock Recommendations - The report recommends specific companies based on various trends, including raw material drug cycles, dual-use item management, and advancements in small nucleic acids [10]. - Companies such as Yuyuan Pharmaceutical, Sunshine Nuohuo, and Yifeng Pharmacy are highlighted for their potential in the current market environment [10].